LiFect293™ Transfection Reagent (4 ml)

Engineered with proprietary lipid-nanoparticle conjugation technology, LiFect293™ transfection reagent represents a next-generation transfection reagent specifically optimized for plasmid transfection in HEK293 lineages and diverse mammalian cell systems. This serum-compatible liposomal formulation integrates novel chemical enhancers that achieve 3-4× higher gene delivery efficiency compared to conventional reagents, while maintaining <15% cytotoxicity in prolonged culture.
 

Key Features

• Unmatched Viral Packaging: Enables lentivirus titers >1×10^8 TU/mL through optimized transfection protocol workflows.

• Megaplasmid Competence: Consistent transfection efficiency for large constructs (up to 180 kb) in adherent & suspension systems (293F/293H).

• Co-transfection Precision: Maintains >90% plasmid transfection equivalence across multiple DNA combinations.

• Process Flexibility: Serum/antibiotic tolerance allows uninterrupted transfection protocol execution in complex media.
 

Applications

293 cells transfection
 

Component

1. LiFect293™ Transfection Reagent: 4 ml
 

Storage

Store at 4°C.
 

Applications

293 cell transfection
 

Component

1. LiFect293™ Transfection Reagent: 1 ml
 

Storage

At 4°C
 

Other Size

Product Name	Cat. #	Price	View
LiFect293™ Transfection Reagent (1 ml)	M0002-01	$199

Case Study

A comparison of transfection efficiency of LiFect293™ reagent with lipofectamine 2000 (L2K) on a hard-to-transfect cell, primary rat aortic smooth muscle cells.
The rat aortic smooth muscle cells were prepared and transfected with pEGFP-N3 by LiFect293™ reagent (left panel) and Lipofecatmine 2000 (L2K, right panel) respectively per manufacturers' protocols. The transfection efficiency was evaluated by detecting GFP fluorescence with a Nikon Eclipse 2000 microscopy 24 hours post transfection.
 

A comparison of transfection efficiency of LiFect293™ reagent with Fugene HD on hard-to-transfect cell, LNCap cells.
The LNCap cells were grown as ATCC recommended procedures and co-transfected with pBabe-hygro-SSeCKs (1.5 µg) and pEGFP-N3 (0.5 µg) per well (6 well plate) LiFect293™ reagent (left panel) and Fugene HD (right panel) respectively per manufacturers' protocols. The transfection efficiency was evaluated by detecting GFP fluorescence with a Nikon Eclipse 2000 microscopy 24 hours post transfection. 

A comparison of LiFect293™ reagent vs. 293fectin, Xfect and Fugene 6 transfection reagents on protein production with suspension 293F cells.
30 ml of 293F cell cultured in standard culture medium was transfected with pEGFP-6x His plasmid using LiFect293™ Transfection Reagent (20 µg plasmid DNA), 293Fectin (30 µg plasmid DNA), Xfect (30 µg plasmid DNA) and Fugene 6 (30 µg plasmid DNA) per manufacturers' standard transfection protocols. GFP fluorescence was visualized 48 hours post transfection (left panel) with A for LiFect293, B for 293fectin, C for Xfect and D for Fugene 6. The 6x His tagged GFP protein was then purified via Ni-NTA affinity column. 5 µl of 1st elution fraction was resolved on SDS-PAGE followed by Coomassie Brilliant Blue staining (right upper panel E) with the lane 1 for LiFect293, lane 2 for protein marker, lane 3 for Xfect, lane 4 for 293fectin and lane 5 for Fugene 6. The protein yield was quantified via spectrometer (right lower panel F).
 

Publications

1. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. 
Publication: Cell        Product: LiFect293™ Transfection Reagent

2. Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles. 
Publication: PNAS        Product: LiFect293™ Transfection Reagent

3. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. 
Publication: Nature Medicine        Product: LiFect293™ Transfection Reagent